Document is current
Any future updates will be listed below
-
Authors
Teel, Aaron https://orcid.org/0000-0002-6957-1632
Grebowicz, Adrian
Lytvyn, Yuliya https://orcid.org/0000-0003-1805-9994
Garner, Stephanie
Appleton, C. Thomas https://orcid.org/0000-0001-7148-0767
Saltman, Alexandra P.
Khalidi, Nader https://orcid.org/0000-0002-8270-2617
Junek, Mats https://orcid.org/0000-0001-8416-3955
Khokhar, Faiza
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 3 June 2025
First Online: 1 October 2025
Declarations
:
: This study received ethics approval from Western University’s Research Ethics Board (REB), the University of Toronto REB, and Hamilton Integrated Research Ethics Board (HiREB). The research was conducted in accordance with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) and the principles outlined in the Declaration of Helsinki. Consent to participate was obtained from patients from case series.
: Not applicable.
: Aaron Teel: none. Adrian Grebowicz: none. Yuliya Lytvyn: none. Stephanie Garner: Advisory boards, grants, etc. for Otsuka, UCB, Sanofi, Novartis, AbbVie, UCB Vasculitis foundation. C. Thomas Appleton: Consultant for Abbvie, Amgen, Bristol Myers Squibb, Celgene, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Hoffman LaRoche, Sandoz, Sanofi-Genzyme, and UCB. Alexandra P. Saltman: none. Nader Khalidi: Grants, consulting fees, honoraria etc. for BMS, AbbVie, Sanofi, Roche, Otsuka, GSK, Mallinckrodt. Mats Junek: Consulting fees from Abbvie and educational support from Roche. Faiza Khokhar: Ad boards, speaker honoraria, or support for conferences etc. for Abbvie. Janssen, Fresenius Kabi, Pfizer, UCB, JAMP pharma corporation.
